Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone

Robin Arcani (1) , Geoffroy Venton (2, 1) , Julien Colle (2, 1) , Pierre Suchon (3) , Vadim Ivanov (1) , Cédric Mercier (1) , Laure Farnault (1) , Pauline Roche (1) , Marina Lafage (4) , Corinne Brunet (1) , Wakil Azouza (1) , Bertrand Pourroy (1) , Raphaelle Fanciullino (1) , Régis Costello (2, 1)

1 LA CONCEPTION - Hôpital de la Conception [CHU - APHM]
2 TAGC - Theories and Approaches of Genomic Complexity
3 Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM]
4 Laboratoire de Génie Génétique [Hôpital de la Timone - APHM]

Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.

Keywords: bortezomib; immunomodulatory therapy; lenalidomide; multiple myeloma

Domains: Life Sciences [q-bio]

Robin Arcani, Geoffroy Venton, Julien Colle, Pierre Suchon, Vadim Ivanov, et al.. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal of Haematology, 2019, ⟨10.1111/ejh.13297⟩. ⟨hal-02267221⟩